Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative Disorders
Recruiting now · Phase 2
Conditions studied: Epstein-Barr Virus-associated Lymphoproliferative Diseases, Chronic Active Epstein-Barr Virus Infection, EBV Associated Lymphoma, Umbilical Cord Blood Transplant
In brief
This clinical trial is designed as a single-arm, two-center, open-label, prospective study. All participants are enrolled in the standard-dose unrelated umbilical cord blood transplantation group to evaluate the efficacy and safety of unrelated umbilical cord blood transplantation in treating Epstein-Barr virus-associated lymphoproliferative disease.
Key facts
- Study ID
- NCT07381738
- Run by
- Fudan University
- People needed
- 80
- Starts
- 2026-01-01
- Expected to finish
- 2028-12-31
- Last updated by the study team
- 2026-02-02
Who can join
Age: 14 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Huadong hospital, Fudan university — Shanghai, Shanghai Municipality, China (enrolling)
- Huashan Hospital, Fudan University — Shanghai, Shanghai Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.